Multiomic Approaches to Metabolic Dysfunction-Associated Steatotic Liver Disease

Description

Presenters review how genomic, trasncriptomic, and other omic technologies can help us understand the causes and inform treatments for MASLD. Experts elaborate on integrative multiomic analyses, genetic subtyping and risk stratification, phenotypic clustering, microbiome analyses, and metabolic and genetic metabolomic profiles as they relate to MASLD.

Journey Maps

Presentations

11:00 AM - 11:15 AM
Nov 08 2025
Washington, D.C.

Integrative Multiomic Analyses of Metabolic Dysfunction-Associated Steatotic Liver Disease

Jin Chai, Presenter
MASLD
11:15 AM - 11:30 AM
Nov 08 2025
Washington, D.C.

Genetic Subtyping and Risk Stratification for Metabolic Dysfunction-Associated Steatotic Liver Disease

Elizabeth Speliotes, MD, MPH, PhD, FAASLD, Presenter
MASLD
11:30 AM - 11:45 AM
Nov 08 2025
Washington, D.C.

Phenotypic Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease

Stefano Romeo, MD, PhD, Presenter
MASLD
11:45 AM - 12:00 PM
Nov 08 2025
Washington, D.C.

Microbiome Analyses of Metabolic Dysfunction-Associated Steatotic Liver Disease

Silvia Sookoian, MD, PhD, FAASLD, Presenter
MASLD
12:00 PM - 12:15 PM
Nov 08 2025
Washington, D.C.

Metabolic and Genetic Metabolomic Profiles in Metabolic Dysfunction-Associated Steatotic Liver Disease

Panu K Luukkonen, MD, PhD, Presenter
MASLD

Objectives

  • Explain how genomics can inform the etiology, risk stratification, and treatment of MASLD.
  • Describe how transcriptomics can inform the etiology, risk stratification, and treatment of MASLD.
  • Recognize how metabolomics and microbiomics can inform the etiology, risk stratification, and treatment of MASLD.
Chair

Elizabeth Speliotes, MD, MPH, PhD, FAASLD

University of Michigan Medical Center